# LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

> **NCT02649673** · PHASE1 · TERMINATED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 34 (actual)

## Conditions studied

- Small Cell Lung Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** LCL161
- **DRUG:** Topotecan
- **DRUG:** Pegylated GCSF (PEG-GCSF)

## Key facts

- **NCT ID:** NCT02649673
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03-23
- **Primary completion:** 2021-07-30
- **Final completion:** 2021-07-30
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Clinical program was discontinued by Novartis
- **Last updated:** 2023-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02649673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02649673, "LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02649673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*